AstraZeneca's COPD Drug Data to Boost Sales Outlook

Dow Jones09-09

1228 GMT - AstraZeneca reported blowout data for its new chronic obstructive pulmonary disease drug, which support sales expectations sharply above current consensus estimates, Citi analysts say in a research note. Full study results from the U.K. pharmaceutical company for its tozorakimab point to potential for a broad use across all populations of COPD patients, the analysts say. Tozorakimab also achieved better data for the subgroup of patients for which Sanofi and Regeneron's Dupixent and GSK's Nucala are approved, they add. As a result, Citi says the data support potential peak sales for tozorakimab of at least its estimate of $7 billion, or roughly double what the current consensus estimate for the drug projects. AstraZeneca shares fall 1.1%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment